Literature DB >> 25783615

Efficacy and safety of SNJ-1656 in primary open-angle glaucoma or ocular hypertension.

Toshihiro Inoue1, Hidenobu Tanihara1, Hideki Tokushige2, Makoto Araie3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25783615     DOI: 10.1111/aos.12641

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  6 in total

Review 1.  Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology.

Authors:  Nuno Moura-Coelho; Joana Tavares Ferreira; Carolina Pereira Bruxelas; Marco Dutra-Medeiros; João Paulo Cunha; Rita Pinto Proença
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-03-07       Impact factor: 3.117

Review 2.  Status of Rho kinase inhibitors in glaucoma therapeutics-an overview.

Authors:  Bhawesh Chandra Saha; Rashmi Kumari; Rakhi Kushumesh; Anita Ambasta; Bibhuti Prasanna Sinha
Journal:  Int Ophthalmol       Date:  2021-08-27       Impact factor: 2.031

Review 3.  Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.

Authors:  Angelo P Tanna; Mark Johnson
Journal:  Ophthalmology       Date:  2018-07-12       Impact factor: 12.079

Review 4.  Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma.

Authors:  Ghadeer Al-Humimat; Ibtisam Marashdeh; Duaa Daradkeh; Karanjit Kooner
Journal:  J Exp Pharmacol       Date:  2021-02-25

Review 5.  Topical Medication Therapy for Glaucoma and Ocular Hypertension.

Authors:  Tao Wang; Linlin Cao; Qikun Jiang; Tianhong Zhang
Journal:  Front Pharmacol       Date:  2021-12-01       Impact factor: 5.810

Review 6.  Newer advances in medical management of glaucoma.

Authors:  Neethu Mohan; Arup Chakrabarti; Nazneen Nazm; Rajvi Mehta; Deepak P Edward
Journal:  Indian J Ophthalmol       Date:  2022-06       Impact factor: 2.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.